XNCR — Xencor Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326732 ·
Last close
$24.50
Market Cap
$1.82B
52W High
$30.61
52W Low
$10.38
ADV30
1,471,877
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 51,221,000 | — | -37,068,000 | -21,729,000 | 724,960,000 | 44,663,000 | 221,732,000 |
| Mar 2026 | 4,516,000 | — | -77,862,000 | -128,916,000 | 736,846,000 | 14,170,000 | 221,213,000 |
| Dec 2025 | 28,237,000 | — | -53,628,000 | -6,653,000 | 875,495,000 | 54,073,000 | 239,908,000 |
| Sep 2025 | 20,999,000 | — | -47,519,000 | -6,027,000 | 868,811,000 | 28,291,000 | 243,495,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-205,814,000
Investing CF
$197,638,000
Financing CF
$8,302,000
CapEx
$-2,471,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.17
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-946,604,000
Inventory
—
Receivables
$42,234,000
ST Investments
$411,789,000
EBIT TTM
$-133,777,000
Pretax Income TTM
$-160,848,000
Interest Exp TTM
$27,071,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$104,973,000
EBITDA
$-205,904,000
Free Cash Flow
$-94,537,504
Enterprise Value
$1,528,621,440
Total Cash
$456,452,000
Total Debt
$170,107,008
Shares Out
74,353,397
Trailing EPS
$-2.16
Book Value
$6.77
ROE
-29.1%
ROA
-16.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 125,576,000 | -177,502,000 | -91,923,000 | 875,495,000 | 239,908,000 | 635,587,000 | -135,117,000 |
| Dec 2024 | 110,493,000 | -178,408,000 | -232,618,000 | 951,945,000 | 277,919,000 | 677,611,000 | -202,188,000 |
| Dec 2023 | 174,615,000 | -132,362,000 | -133,133,000 | 965,135,000 | 303,048,000 | 661,750,000 | -77,926,000 |
| Dec 2022 | 164,579,000 | -82,473,000 | -55,181,000 | 846,266,000 | 118,770,000 | 727,496,000 | 24,485,000 |
TTM Snapshot
Revenues TTM
$97,360,000
NetIncome TTM
$-172,421,000
OpCashFlow TTM
—
Assets (Latest)
$736,846,000
Forward EPS
$-3.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $1.83B | $12.82 | — |
| GPCR | Structure Therapeutics Inc. | $1.83B | $25.67 | — |
| URGN | UroGen Pharma Ltd. | $1.81B | $36.98 | — |
| BHVN | Biohaven Ltd. | $1.80B | $11.93 | — |
| GENB | Generate Biomedicines, Inc. | $1.80B | $13.99 | — |
News headlines (Yahoo Finance, 1h cache)
Raymond James Updates Healthcare Top Picks for October
2026-10-01 20:26 · Yahoo
Xencor to Present at the 2026 Cantor Global Healthcare Conference
2026-09-02 20:01 · Yahoo
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
2026-08-08 12:12 · Yahoo
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 21:25 · Yahoo
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
2026-07-20 11:26 · Yahoo
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
2026-07-17 13:11 · Yahoo
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
2026-06-14 05:11 · Yahoo
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
2026-09-07 17:00 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-07-30 19:46 · Yahoo
Xencor Reports Second Quarter 2026 Financial Results
2026-08-05 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.